Non-ruptured AAA
13722✅vs 13722❎
Propensity-matching
5 yr f/up
TriNetX network
Rupture 2.4➡️1.6%
Elective repair 3.0➡️2.1%
MACE 54.1➡️48.2%
All-cause mortality 20.2➡️13.0%
#JVascSurg 2026
www.sciencedirect.com/science/arti...
Non-ruptured AAA
13722✅vs 13722❎
Propensity-matching
5 yr f/up
TriNetX network
Rupture 2.4➡️1.6%
Elective repair 3.0➡️2.1%
MACE 54.1➡️48.2%
All-cause mortality 20.2➡️13.0%
#JVascSurg 2026
www.sciencedirect.com/science/arti...
過体重/肥満2型DM、PSマッチ可能だった67,608×2例比較——
・チルゼパチド開始後1年間で2.1%に「栄養性貧血」。
・GLP-1RAなら2.8%。
抄録🔗 qr.paps.jp/1i3U1
過体重/肥満2型DM、PSマッチ可能だった67,608×2例比較——
・チルゼパチド開始後1年間で2.1%に「栄養性貧血」。
・GLP-1RAなら2.8%。
抄録🔗 qr.paps.jp/1i3U1
#Bronchiectasis
#Bronchiectasis
🔎 TriNetX study of SLE
🖥️ PREVENT calculator of HF, CVD risk and its performance
🤔 I think the first time I’ve seen TriNetX used for CV risk estimation in rheum
#ACR26
🔎 TriNetX study of SLE
🖥️ PREVENT calculator of HF, CVD risk and its performance
🤔 I think the first time I’ve seen TriNetX used for CV risk estimation in rheum
#ACR26
🔎 TriNetX study: PsA pop, looking JAKi and MACE, VTE risk
👉️TNFi and IL17i both had lower risk vs JAKi in this study but usual TriNetX platform caveats apply
#ACR26
🔎 TriNetX study: PsA pop, looking JAKi and MACE, VTE risk
👉️TNFi and IL17i both had lower risk vs JAKi in this study but usual TriNetX platform caveats apply
#ACR26
📊 TriNetX: PsA and GLP1-RA use
🔎 outcomes: synovitis, stiffness, pain, steroid use – will have to ask how they defined these in TriNetX because with diagnostic coding, it’s hard to capture the synovitis, stiffness, pain symptoms 🤔
#ACR26
📊 TriNetX: PsA and GLP1-RA use
🔎 outcomes: synovitis, stiffness, pain, steroid use – will have to ask how they defined these in TriNetX because with diagnostic coding, it’s hard to capture the synovitis, stiffness, pain symptoms 🤔
#ACR26
⭐ Abs 0712 Kasiraj
🔎 TriNetX study looking at gout & T2DM population on GLP1-RA vs DPP4i with outcomes of gout flares; HF, MACE; CKD; death
#ACR26
⭐ Abs 0712 Kasiraj
🔎 TriNetX study looking at gout & T2DM population on GLP1-RA vs DPP4i with outcomes of gout flares; HF, MACE; CKD; death
#ACR26
🔎 TriNetX target trial emulation
📊 study pop: T2DM + obesity
🔎 Exposure: GLP1-RA use vs SGLT2i
🔎 Outcomes: incident OA (HR 1.17), arthroplasty (HR 1.21)
#ACR26
🔎 TriNetX target trial emulation
📊 study pop: T2DM + obesity
🔎 Exposure: GLP1-RA use vs SGLT2i
🔎 Outcomes: incident OA (HR 1.17), arthroplasty (HR 1.21)
#ACR26
📊 SLR – PsO and PsA risk
n=11 studies
👉️protective for IL23i vs TNFi; pooled HR 0.6
📌 does include our study using TriNetX - pubmed.ncbi.nlm.nih.gov/38251522/
#ACR26
📊 SLR – PsO and PsA risk
n=11 studies
👉️protective for IL23i vs TNFi; pooled HR 0.6
📌 does include our study using TriNetX - pubmed.ncbi.nlm.nih.gov/38251522/
#ACR26
📊 TriNetX study: gout & allopurinol initiators
🔎 looked at self reported race and AHS risk - goes back to the last set of ACR gout guidelines and who should get screen for HLA-B5801
#ACR26
📊 TriNetX study: gout & allopurinol initiators
🔎 looked at self reported race and AHS risk - goes back to the last set of ACR gout guidelines and who should get screen for HLA-B5801
#ACR26
Most of these used TriNetX and propensity score methods within the platform, so please read interpretations with caution
Most of these used TriNetX and propensity score methods within the platform, so please read interpretations with caution
🔎 TriNetX to study TKR risk of CPPD+OA vs OA alone
👉️With CPPD, HR 1.29-1.53 for TKR risk vs OA alone
👉️Another study pointing to the additional impact of intra-articular crystal deposition/calcification on OA
#ACR26
🔎 TriNetX to study TKR risk of CPPD+OA vs OA alone
👉️With CPPD, HR 1.29-1.53 for TKR risk vs OA alone
👉️Another study pointing to the additional impact of intra-articular crystal deposition/calcification on OA
#ACR26
authors explain they expected confounding by indication to bias in the direction of RTX having higher risk of poor outcomes
#ACR26
authors explain they expected confounding by indication to bias in the direction of RTX having higher risk of poor outcomes
#ACR26
📊 TriNetX study
🔎 wanted to look at new IgG4RD code (10/2023) and FDA approval for inebrilizumab (4/2025)
🔎 exposure: RTX vs conventional IST
#ACR26
📊 TriNetX study
🔎 wanted to look at new IgG4RD code (10/2023) and FDA approval for inebrilizumab (4/2025)
🔎 exposure: RTX vs conventional IST
#ACR26